0001213900-24-024022.txt : 20240319 0001213900-24-024022.hdr.sgml : 20240319 20240319161034 ACCESSION NUMBER: 0001213900-24-024022 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240319 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240319 DATE AS OF CHANGE: 20240319 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RELMADA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001553643 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 455401931 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39082 FILM NUMBER: 24763286 BUSINESS ADDRESS: STREET 1: 2222 PONCE DE LEON BLVD. 3RD FLOOR CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: 646 876 3459 MAIL ADDRESS: STREET 1: 2222 PONCE DE LEON BLVD. 3RD FLOOR CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CAMP NINE, INC. DATE OF NAME CHANGE: 20120706 8-K 1 ea0202135-8k_relmada.htm CURRENT REPORT
false 0001553643 0001553643 2024-03-19 2024-03-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 19, 2024

 

RELMADA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-39082   45-5401931
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

2222 Ponce de Leon Blvd., Floor 3

Coral Gables, FL

   33134
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (786) 629-1376

 

 
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol    Name of exchange on which registered
Common stock, $0.001 par value per share   RLMD   The NASDAQ Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On March 19, 2024, Relmada Therapeutics, Inc. (the “Company”) issued a press release providing a corporate update and reporting its financial results for the fourth quarter and full year ended December 31, 2023. (These results are preliminary and unaudited.) The Company also announced that it would conduct a conference call and audio webcast on March 19, 2024, at 4:30 PM EDT/1:30 PM PDT, to discuss the update and results. The Company’s complete audited financial statements and notes thereto as of, and for the fiscal years ended, December 31, 2023 and 2022, will be contained in its Annual Report on Form 10-K to be filed with the Securities and Exchange Commission. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 2.02 by reference.

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. 

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press release dated March 19, 2024, regarding corporate update and fourth quarter and full year 2023 financial results
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: March 19, 2024 RELMADA THERAPEUTICS, INC.
     
  By: /s/ Sergio Traversa
  Name: Sergio Traversa
  Title: Chief Executive Officer

 

 

2

 

 

 EX-99.1 2 ea020213501ex99-1_relmada.htm PRESS RELEASE DATED MARCH 19, 2024, REGARDING CORPORATE UPDATE AND FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS

Exhibit 99.1

 

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

 

CORAL GABLES, Fla., Mar 19, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the fourth quarter and full year ended December 31, 2023. The Company will host a conference call today, Tuesday, March 19, at 4:30 PM Eastern Time/1:30 PM Pacific Time.

 

 

 

“We continue to make solid progress in advancing our ongoing Phase 3 program for REL-1017 as an adjunctive treatment for major depressive disorder (MDD),” said Sergio Traversa, Relmada’s Chief Executive Officer. “Enrollment in the ongoing Reliance II (study 302) is steadily proceeding, and we expect top line data in the second half of 2024. In our second Phase 3 trial for REL-1017, Relight (study 304), we began dosing patients during the third quarter of last year, and we plan to complete enrollment in this study by year-end 2024.”

 

“In our promising low dose metabolic psilocybin program (REL-P11) , which showed significant therapeutic potential on multiple parameters in pre-clinical rodent studies, we intend to initiate a single-ascending dose Phase 1 trial in obese patients in the first half of this year to define the pharmacokinetic, safety, and tolerability profile of our modified-release psilocybin formulation in this population,” continued Mr. Traversa. “This will be followed by a Phase 2a trial to establish clinical proof-of-concept.”

 

Recent Corporate Highlights

 

●Presented new preclinical data on its novel psilocybin at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2023® 2023 in November 2023

 

●Appointed Dr. Andrew Cutler as Senior Clinical Development Advisor. Dr. Cutler has been conducting clinical research since 1993 and has been a Principal Investigator on over 400 clinical trials in a variety of CNS and medical indications, focusing on MDD, Bipolar Disorder, ADHD and Schizophrenia in children, adolescents and adults.

 

Upcoming Anticipated Milestones

 

●Complete enrollment in ongoing RELIANCE II, which is planned to enroll approximately 300 patients, with top-line data in the second half of 2024.

 

●Complete enrollment in the Relight study (study 304), which is planned to enroll approximately 300 patients, by year-end 2024.

 

●Commence a Phase 1 trial in obese patients in the first half of 2024 to define the pharmacokinetic, safety and tolerability profile of the Company’s modified-release psilocybin formulation (REL-P11), followed by a Phase 2a trial to establish clinical proof-of-concept with data expected in the first half of 2025.

 

 

 

 

Fourth Quarter 2023 Financial Results

 

●Research and development expense for the three months ended December 31, 2023, totaled $14.8 million, compared to $26.9 million for the three months ended December 31, 2022. The decrease was primarily driven by a decrease in study costs associated with the completion of two Phase 3 trials and the long-term, open-label, safety trial (Study 310).

 

●General and administrative expense for the three months ended December 31, 2023, totaled $12.1 million compared to $11.8 million for the three months ended December 31, 2022, an increase of approximately $0.3 million. The increase was primarily driven by an increase in compensation expense due to higher employee-related costs.

 

●Net cash used in operating activities for the three months ended December 31, 2023, totaled $10.3 million compared to $35.9 million for the three months ended December 31, 2022.

 

●The net loss for the three months ended December 31, 2023, was $25.2 million, or $0.84 per basic and diluted share, compared with a net loss of $37.9 million, or $1.28 per basic and diluted share, for the three months ended December 31, 2022.

 

Full-Year 2023 Financial Results

 

●Research and development expense for the year ended December 31, 2023, totaled $54.8 million, compared to $113.3 million for the year ended December 31, 2022. The decrease was primarily driven by a decrease in study costs associated with the completion of two Phase 3 trials and the long-term, open-label, safety trial (Study 310).

 

●General and administrative expense for the year ended December 31, 2023, totaled $48.9 million, compared to $47.9 million for the year ended December 31, 2022. The increase was primarily driven by an increase in compensation.

 

●Net cash used in operating activities for the year ended December 31, 2023, totaled $51.7 million, compared to $103.8 million for the year ended December 31, 2022.

 

●Net loss for the year ended December 31, 2023 and 2022 was $98.8 million and $157.0 million, respectively. The Company had a net loss of $3.28 and $5.30 per basic and diluted share for the year ended December 31, 2023 and 2022, respectively.

 

●As of December 31, 2023, the Company had cash, cash equivalents, and short-term investments of approximately $96.3 million, compared to cash, cash equivalents, and short-term investments of approximately $148.3 million at December 31, 2022.

 

2

 

 

Conference Call and Webcast Details

 

Tuesday, March 19th @ 4:30pm ET

Toll Free: 888-886-7786
International: 416-764-8658
Conference ID: 35626110
Webcast: Click Here

 

About REL-1017

 

REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the adjunctive treatment of major depressive disorder (MDD). Relmada’s ongoing clinical research program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. The development program for REL-1017 as an adjunctive treatment for MDD includes two Phase 3 randomized, double-blind, placebo-controlled studies, Reliance II (Study 302) and Relight (Study 304). Reliance II and Relight have the same key study design parameters.

 

About REL-P11

 

Relmada acquired the development and commercial rights to a novel psilocybin and derivatives program in July of 2021. Psilocybin has neuroplastogen™ effects that have the potential to ameliorate neurodegenerative conditions. The pleiotropic metabolic effects of low-dose psilocybin were discovered while studying its neuroplastogen™ potential in a rodent model deficient in neurogenesis – obese rats maintained on a high fructose, high fat diet (HFHFD), and were then replicated in mice.

 

About Relmada Therapeutics, Inc.

 

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada’s experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada’s lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.

 

Forward-Looking Statements

 

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “expects,” “anticipates,” “believes,” “will,” “will likely result,” “will continue,” “plans to,” “potential,” “promising,” and similar expressions. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of clinical trial results to demonstrate statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of the 310 open-label study to accurately reflect the results of the ongoing 302 and 304 blinded, randomized and controlled studies, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, failure of the planned psilocybin Phase 1 and Phase 2a trials to be successfully initiated and carried out, and the other risk factors described under the heading “Risk Factors” set forth in the Company’s reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

 

Investor Contact:

 

Tim McCarthy

LifeSci Advisors

Tim@LifeSciAdvisors.com

 

Media Inquiries:

 

Corporate Communications

media@relmada.com

 

3

 

 

Relmada Therapeutics, Inc.

Consolidated Balance Sheets

(Unaudited)

 

   As of   As of 
   December 31,   December 31, 
   2023   2022 
Assets        
Current assets:        
Cash and cash equivalents  $4,091,568   $5,395,905 
Short-term investments   92,232,292    142,926,781 
Other receivables   -    512,432 
Prepaid expenses   1,185,057    4,035,186 
Total current assets   97,508,917    152,870,304 
Other assets   43,125    34,875 
Total assets  $97,552,042   $152,905,179 
           
Liabilities and Stockholders’ Equity          
Current liabilities:          
Accounts payable  $3,506,009   $5,261,936 
Accrued expenses   8,688,791    7,206,941 
Total current liabilities   12,194,800    12,468,877 
Total liabilities   12,194,800    12,468,877 
           
Commitments and Contingencies (Note 7)          
           
Stockholders’ Equity:          
Preferred stock, $0.001 par value, 200,000,000 shares authorized, none issued and outstanding   -    - 
Class A convertible preferred stock, $0.001 par value, 3,500,000 shares authorized, none issued and outstanding   -    - 
Common stock, $0.001 par value, 150,000,000 shares authorized, 30,099,203 and 30,099,203 shares issued and outstanding, respectively   30,099    30,099 
Additional paid-in capital   646,229,824    602,517,138 
Accumulated deficit   (560,902,681)   (462,110,935)
Total stockholders’ equity   85,357,242    140,436,302 
Total liabilities and stockholders’ equity  $97,552,042   $152,905,179 

 

4

 

 

Relmada Therapeutics, Inc.

Consolidated Statements of Operations

(Unaudited)

 

   2023   2022 
Operating expenses:        
Research and development  $54,807,348   $113,322,999 
General and administrative   48,894,945    47,926,077 
Total operating expenses   103,702,293    161,249,076 
           
Loss from operations   (103,702,293)   (161,249,076)
           
Other income (expenses):          
Gain on settlement of fees   -    6,351,606 
Interest/investment income, net   5,151,704    2,659,424 
Realized loss on short-term investments   (4,064,391)   (585,522)
Unrealized gain (loss) on short-term investments   3,823,234    (4,220,255)
Total other income (expenses), net   4,910,547    4,205,253 
           
Net loss  $(98,791,746)  $(157,043,823)
           
Net loss per common share – basic and diluted  $(3.28)  $(5.30)
           
Weighted average number of common shares outstanding – basic and diluted   30,099,203    29,628,664 

 

5

 

 

Relmada Therapeutics, Inc.

Consolidated Statements of Changes in Stockholders’ Equity

For the Years Ended December 31, 2023 and 2022 

 

   Common Stock   Additional
Paid-in		   Accumulated     
   Shares   Par Value   Capital   Deficit   Total 
Balance – December 31, 2021   27,740,147   $27,740   $513,304,258   $(305,067,112)  $208,264,886 
Stock-based compensation expense   -    -    44,194,765    -    44,194,765 
ATM offering, net   2,094,243    2,094    42,726,505    -    42,728,599 
Share exchange – Prefunded warrants, net of fees   (1,452,016)   (1,452)   (48,548)   -    (50,000)
Net exercise – Prefunded warrants   1,451,795    1,452    (1,452)   -    - 
Warrants exercised   181,336    181    1,264,342    -    1,264,523 
Options exercised   83,698    84    703,636    -    703,720 
Short swing profit, net   -    -    373,632    -    373,632 
Net loss   -    -    -    (157,043,823)   (157,043,823)
Balance – December 31, 2022   30,099,203    30,099    602,517,138    (462,110,935)   140,436,302 
Stock-based compensation expense   -    -    43,811,149    -    43,811,149 
ATM fees   -    -    (98,463)   -    (98,463)
Net loss   -    -    -    (98,791,746)   (98,791,746)
Balance – December 31, 2023   30,099,203   $30,099   $646,229,824   $(560,902,681)  $85,357,242 

 

6

 

 

Relmada Therapeutics, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

 

   2023   2022 
Cash flows from operating activities        
Net loss  $(98,791,746)  $(157,043,823)
Adjustments to reconcile net loss to net cash used in operating activities:          
Stock-based compensation   43,811,149    44,194,765 
Gain on settlement   -    (6,351,606)
Realized loss on short-term investments   4,064,391    585,522 
Unrealized (gain) loss on short-term investments   (3,823,234)   4,220,255 
Change in operating assets and liabilities:          
Lease payment receivable   -    86,377 
Other receivable   512,432    (512,432)
Prepaid expenses and other assets   2,841,879    7,259,767 
Accounts payable   (1,755,927)   421,040 
Accrued expenses   1,481,850    3,338,518 
Net cash used in operating activities   (51,659,206)   (103,801,617)
           
Cash flows from investing activities          
Purchase of short-term investments   (90,463,532)   (47,293,763)
Sale of short-term investments   140,916,864    67,027,372 
Net cash provided by investing activities   50,453,332    19,733,609 
           
Cash flows from financing activities          
Payment of ATM fees   (98,463)   - 
Payment of fees for warrants issued for common stock   -    (50,000)
Proceeds from issuance of common stock   -    42,728,599 
Proceeds from options exercised for common stock   -    703,720 
Proceeds from warrants exercised for common stock   -    1,264,523 
Proceeds from short swing profit, net   -    373,632 
Net cash (used in) provided by financing activities   (98,463)   45,020,474 
           
Net decrease in cash and cash equivalents   (1,304,337)   (39,047,534)
Cash and cash equivalents at beginning of the period   5,395,905    44,443,439 
Cash and cash equivalents at end of the period  $4,091,568   $5,395,905 

 

 

7

 

 

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end EX-101.SCH 4 rlmd-20240319.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 rlmd-20240319_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 rlmd-20240319_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover
Mar. 19, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 19, 2024
Entity File Number 001-39082
Entity Registrant Name RELMADA THERAPEUTICS, INC.
Entity Central Index Key 0001553643
Entity Tax Identification Number 45-5401931
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 2222 Ponce de Leon Blvd.
Entity Address, Address Line Two  Floor 3
Entity Address, City or Town Coral Gables
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33134
City Area Code 786
Local Phone Number 629-1376
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.001 par value per share
Trading Symbol RLMD
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://relmada.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea0202135-8k_relmada.htm rlmd-20240319.xsd rlmd-20240319_lab.xml rlmd-20240319_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0202135-8k_relmada.htm": { "nsprefix": "RLMD", "nsuri": "http://relmada.com/20240319", "dts": { "inline": { "local": [ "ea0202135-8k_relmada.htm" ] }, "schema": { "local": [ "rlmd-20240319.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "rlmd-20240319_lab.xml" ] }, "presentationLink": { "local": [ "rlmd-20240319_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://relmada.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0202135-8k_relmada.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-19", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0202135-8k_relmada.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://relmada.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001213900-24-024022-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-024022-xbrl.zip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end XML 18 ea0202135-8k_relmada_htm.xml IDEA: XBRL DOCUMENT 0001553643 2024-03-19 2024-03-19 iso4217:USD shares iso4217:USD shares false 0001553643 8-K 2024-03-19 RELMADA THERAPEUTICS, INC. NV 001-39082 45-5401931 2222 Ponce de Leon Blvd.  Floor 3 Coral Gables FL 33134 786 629-1376 false false false false Common stock, $0.001 par value per share RLMD NASDAQ false